Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis

American Journal of Hematology

Volumn 86, Issue 4, 2011, Pages 343-345

  Pardanani, Animesh ^a   Begna, Kebede ^a   Finke, Christy ^a   Lasho, Terra ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; POMALIDOMIDE; PREDNISONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHEMOKINE CCL2; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-8; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PRIMARY MYELOFIBROSIS; RECEPTORS, INTERLEUKIN-2; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79953045011     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21972     Document Type: Article

References (19)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.
2. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194.
3. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9-16.
4. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997; 90: 4369-4383.
5. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 2002; 100: 1123-1132.
6. Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: Insights into the pathophysiology of osteomyelofibrosis. J Immunol 1998; 160: 691-699.
7. Rameshwar P, Narayanan R, Qian J, et al. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: An inflammatory response beyond the realm of homeostasis. J Immunol 2000; 165: 2271-2277.
8. Tefferi A, Vaidya R, Caramazza D, et al. Circulating IL-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol, in press.
9. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: A refined dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol. 2010 Dec 13. [Epub ahead of print].
10. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232-5240.
11. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
12. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
13. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Jan 10. [Epub ahead of print].
14. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
15. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2010 Nov 5. [Epub ahead of print].
16. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010; 85: 129-130.
17. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
18. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia. 2011 Jan;25(1): 82-8.
19. Tefferi A, Barosi G, Mesa RA, et al. International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 2006; 108: 1497-1503.